Palace Aide Issues King Charles Cancer Update, Says He's Trying to Keep Life "As Normal as Possible"
When you buy through links on our articles, Future and its syndication partners may earn a commission.
There haven't been many updates on King Charles's health since he was diagnosed with cancer in February 2024, but a senior royal aide has spoken out after The King and Queen Camilla visited Canada this week.
"The thing you learn about this illness is that you just manage it," the palace staffer said, via Hello! "And that's what he does. Medical science has made incredible advances and I genuinely see no difference in him."
The aide continued, "As long as you just do what the doctors say, just live your life as normal as possible and that's exactly what he is doing."
The King—who has not revealed the exact type of cancer he has—receives regular outpatient treatments at The London Clinic. "It's no secret that he is still having treatment but because he is incredibly fit, he is just dealing with it all incredibly well," the royal aide said. "As everybody knows he is driven by duty, so he just gets on with it."
Indeed, The King is so "driven by duty" that no one can get him to slow down other than Queen Camilla.
Per his aide, staffers have been "planning the programme as usual, trying to lighten it a little bit" following Their Majesties' tiring trip to Canada. However, the hardworking monarch doesn't seem to be keen on reducing his schedule, with the staffer noting his team has not had "much success" in that matter.
In April, a senior aide to The King said, per The Sun, "We've all tried!" when asked about getting the monarch to relax on his duties. The employee added, "But as people will have seen, The King enjoys his work." Even after he was briefly hospitalized due to side effects from cancer treatment this spring, King Charles was back to duties as usual and traveled to Rome with Queen Camilla for an official state visit.
The Queen agreed that her husband "loves his work and it keeps him going." She added, "And I think it's wonderful, you know, if you've been ill and you are recovering, you're getting better and now he wants to do more and more and more. That's the problem."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
23 minutes ago
- Medscape
Lysosomal Iron Catalyzes Cell Death in Resistant Cancers
A team from French research institutes Centre national de la recherche scientifique (CNRS), Institut Curie, and Institut national de la santé et de la recherche médicale (Inserm) has discovered a new class of molecules capable of inducing the death of cancer cells that are resistant to standard treatments. The study was published in Nature on May 7. Harnessing Iron's Properties in Cancer Cells 'In certain cancers, such as pancreatic cancer or sarcomas, therapeutic options are relatively limited,' Raphaël Rodriguez, research director at CNRS and co-author of the study, told Medscape's French edition . Current cancer treatments mainly target primary tumor cells but often fail to eliminate cells with metastatic potential, which are responsible for 70% of cancer-related deaths. To address this, the team developed a new class of molecules — phospholipid degraders — designed to destroy cancer cell membranes and trigger cell death via ferroptosis. 'We used the properties of iron in cancer cells with metastatic potential. These cells express high levels of the CD44 protein on their surface, which allows them to internalize iron — a resource they need to transform and adapt to standard treatments,' Rodriguez explained. This transformation, however, also makes them more vulnerable to ferroptosis, a form of cell death catalyzed by iron. Within lysosomes — the small organelles that break down cellular debris and foreign material — iron reacts with hydrogen peroxide, generating oxygen radicals. These radicals damage lysosomal membranes and initiate a chain reaction that spreads throughout the cell, leading to the formation of peroxidized lipids in the membranes of other organelles and ultimately causing cell death. 'We were the first to link cancer, adaptability, and vulnerability to ferroptosis. Cancer cells can adapt, but they don't have a thousand identities. They have two: one that proliferates and one that spreads. Today, we target proliferation. We also need to target dissemination,' said Rodriguez. Phospholipid Degraders The researchers developed phospholipid degraders that activate ferroptosis. These molecules contain one segment that targets the cell membrane, enabling penetration and accumulation in lysosomes. A second segment enhances iron reactivity in these compartments of pro-metastatic cancer cells, triggering ferroptosis. The molecules, named fentomycin-1 (Fento-1), were made fluorescent to confirm their lysosomal localization using fluorescence microscopy. 'Ferroptosis results from the cell's inability to repair membrane damage,' Rodriguez summarized. Reduction in Tumor Growth Tested on primary patient-derived cells, tumor organoids, human biopsies, and immunocompetent animal models, these molecules demonstrated greater efficacy than standard treatments. In preclinical models of metastatic breast cancer, Fento-1 led to a significant reduction in tumor growth. It also showed strong cytotoxic effects in biopsies of pancreatic cancers and angiosarcomas. 'The most interesting results come when we combine these molecules with current treatments. The response is even better,' emphasized Rodriguez. 'We're not saying our treatment will replace existing therapies. We need a combination,' he added. The next steps include toxicity studies, followed by clinical trials. 'Industry and investors should be interested in developing this new therapeutic strategy.' This work was supported by the Ligue Contre le Cancer (Les équipes labellisées), the European Union's Horizon 2020 research and innovation programme, Fondation pour la Recherche Médicale, Fondation Charles Defforey - Institut de France, Klaus Grohe Foundation, Institut National du Cancer, Région Île-de-France, the French National Research Agency, Fondation Bettencourt Schueller, CNRS, Institut Curie, and Inserm.
Medscape
2 hours ago
- Medscape
AI Scribes Cutting GPs' Admin and Boosting Patient Care
Artificial intelligence (AI) scribing tools are increasingly being used in NHS settings to enhance patient care and free up staff time. In April, the Department of Health and Social Care announced support for NHS doctors to adopt AI tools that 'bulldoze bureaucracy,' allowing clinicians to focus more on their patients and less on documentation. This follows a multi-site evaluation led by Great Ormond Street Hospital for Children, London, England, and funded by NHS England. The trial tested ambient voice technologies (AVTs) that listen to and transcribe consultations in real time. More than 7000 patients took part across settings including accident and emergency, primary care, community services, and mental health. Interim data from the trial showed increased productivity and more time spent on direct care, particularly in emergency settings. Current AI Scribing Tools in Use Several AI scribing tools are already being used within the NHS. Health technology company Accurx recently teamed up with Tandem Health to launch Accurx Scribe, a tool that can transcribe, summarise, and code patient consultations into a trust's clinical records, with functionality to write back to EMIS and SystmOne. It is currently being rolled out across GP practices using Accurx. At the Royal Wolverhampton NHS Trust, a pilot of CLEARNotes is underway. The tool listens to patient consultations and generates a structured summary of the discussion. Meanwhile, Heidi Health is being used by about 40% of GPs and is being piloted in 15 NHS trusts. The AVT tool provides real-time transcription, without storing audio files, in order to address patients' privacy concerns. GP Practices See Significant Benefits At Modality, a group of general practices in West Yorkshire, Heidi has been installed for all GPs and advanced clinical practitioners. Tom Ratcliffe, a GP partner and digital transformation clinical lead for the group, said: 'Clinicians find that it saves time and reduces their administrative burden, particularly around generating clinical correspondence after consultations.' Tom Ratcliffe Ratcliffe described using an AI scribing tool as 'quite transformative' and particularly beneficial for clinicians who are slower typists or who take longer to write detailed notes. 'One of the really significant benefits we've experienced is that by having an ambient scribe writing the notes while you're speaking with a patient, it enables you to focus more on them,' he told Medscape News UK . 'That's really important, as you're then picking up on non-verbal cues that you can easily miss when you're distracted by the computer.' With GPs having between 30 and 50 clinical contacts per day, 'having to think about exactly what to write for each of those encounters is quite a drain on your mental capacity,' Ratcliffe said. 'My colleagues and I have all found using an ambient scribe helps to reduce your cognitive load. Having a consistent format for the notes for every encounter is also helpful,' he added. Patient Consent and Data Security Educating patients about the software is an important consideration. Thomas Kelly, co-founder and chief executive of Heidi Health, said clinicians are advised to obtain consent before using the tool and to explain to patients how an AI scribe works and what they can expect during a consultation. Thomas Kelly 'Patients can also learn more through a range of resources that GPs can put up in their practices that explain how Heidi works,' Kelly said. A transcription of the consultation will be generated, 'but the audio is not permanently recorded or stored in a way that could ever be breached,' he explained. 'It's just being turned into that documentation in real time, and this process is happening on Heidi's servers in the UK.' However, when a session is deleted from Heidi's servers, 'it's deleted for everyone, and there is no way it can be retrieved.' Ratcliffe said that patients have reacted positively to their Modality GP using an AI scribing tool. 'With all the digital innovations we've introduced, we've always had patients who raised very reasonable questions about the privacy of their data,' he said. 'But the level of patient acceptance of using Heidi has been incredibly high.' Each patient is asked to give their consent for the scribing tool to be used. 'I haven't heard of a single example of a patient declining use in an encounter, and we've done probably hundreds or thousands of these now,' said Ratcliffe. Accuracy Concerns Addressed Andrew Noble works within the frailty service at Jean Bishop Integrated Care Centre in East Hull, England. He uses Heidi for consultations lasting up to an hour, which require lengthy administration time. Andrew Noble Staff training on the system emphasises vigilance about possible AI hallucinations in output. According to Noble, one or two minor errors might occur during an hour-long consultation transcription. However, for shorter appointments, lasting 15 minutes, clinicians might expect error-free note-taking from the AI scribe. Use of the tool has significantly improved the quality of note-taking. 'The Heidi AI scribe halved the number of spelling mistakes, and it reduced the number of abbreviations quite significantly as well,' said Noble. Mistakes might include US spellings of antibiotics or the scribe mishearing the name of a medication. 'But we do have human error when inputting our own notes, so those things were already happening from time to time,' Noble observed. Ratcliffe tested multiple AI scribe options before selecting Heidi Health. All platforms occasionally made minor errors. 'Anyone who uses any form of generative AI does find it will occasionally confabulate or hallucinate,' he said. 'One of the key parts of our training was around educating clinicians on the importance of understanding that their role has gone from spending lots of time typing up notes to carefully reading a transcript and checking for any potential issues.' Overall, 'we haven't found that the error rate is high enough that means it's unsafe or not practical to use,' said Ratcliffe. Game-Changing Technology? Health Secretary Wes Streeting has described AI as a catalyst that will revolutionise healthcare. GPs appear to share this optimism. 'This was something that we worked really hard to roll out quickly because we did feel that it was game-changing,' Ratcliffe explained. 'I think it has been game-changing for a lot of our clinicians. When used properly, it can make a big difference.' With GPs working 'above and beyond,' Ratcliffe believes that AI scribing tools 'could help us to move back to a safer place in terms of making our workload more manageable.'
Yahoo
2 hours ago
- Yahoo
Why men with broken heart syndrome are more likely to die, according to experts
Get inspired by a weekly roundup on living well, made simple. Sign up for CNN's Life, But Better newsletter for information and tools designed to improve your well-being. A 59-year-old man arrived at the Peking University First Hospital in Beijing for a procedure when he started having severe chest pain and shortness of breath. Four months earlier, he had cancerous tumors removed from his bladder. Around his family, he tried his best to appear strong and avoided discussions of his health. Privately, his severe anxiety over the possibility of a cancer recurrence kept him awake at night. Doctors said the man was experiencing takotsubo cardiomyopathy — also known as broken heart syndrome, as documented in a 2021 case study. The rare stress-induced heart condition has been observed primarily in women, but a study published in the Journal of the American Heart Association in May found that the illness may be more deadly for the men who get it. Thought to be caused by extreme emotional or physical events — such as learning about the death of a loved one, winning the lottery or lifting a heavy sofa — takotsubo cardiomyopathy, or TC, occurs when the heart muscle is flooded with stress hormones, causing part of it to 'freeze' in place. As the heart struggles to properly pump blood, symptoms resemble those of a heart attack, including chest pain, heart palpitations and irregular heartbeat. The new study analyzed data from nearly 200,000 patients hospitalized for TC in the United States between 2016 and 2020. While women accounted for 83% of the cases, men were more than twice as likely to die from the condition — with a mortality rate of 11.2%. 'The differences between men and women are a very striking finding,' said study coauthor Dr. Mohammad Reza Movahed, a clinical professor of medicine at the University of Arizona in Tucson. 'It raises a new, interesting question that should really be studied.' Similar to differences between men's and women's cardiovascular health more generally, the discrepancies in TC death rates are not well understood, Movahed said, especially because they counter trends in other heart diseases. It's widely theorized, however, that differences in hormone levels play a role. Stressful situations trigger the adrenal glands to release our fight-or-flight hormones, called catecholamines. They are meant to increase our blood pressure and raise our heart rate, but extreme levels can temporarily 'stun' cells in the heart's tissue, leading to TC, Movahed explained. Men are thought to produce more catecholamines during stressful situations compared with women, possibly leading men to present with more severe cases of TC, he suggested. Estrogen, a sex hormone produced at higher levels in women, may also have a protective effect on the cardiovascular system, making it easier to manage an extreme influx of catecholamines and reducing the risk of severe complications from TC, said Dr. Louis Vincent, a noninvasive-cardiology research fellow at the University of Miami, who coauthored a similar, multiyear study investigating discrepancies in men and women who had TC. Vincent was not involved in the new study. Beyond biological differences, social factors may play a role as well. 'Most (physicians) know about takotsubo, but they may think of it as a disease just affecting women, so the diagnosis might be overlooked in men,' said Dr. Deepak Bhatt, a cardiologist and the director of Mount Sinai Fuster Heart Hospital who was not involved in the study. 'With misdiagnosis, care is delayed, and that can sometimes lead to worse outcomes.' Men may also seek care at a later stage of illness, believing that their symptoms are manageable or may pass, said Dr. Alejandro Lemor, an assistant professor of interventional cardiology at the University of Mississippi Medical Center who was also not involved in the study. Deadly complications from TC include blood clots, stroke, cardiac arrest and heart failure, Lemor said. If the condition is caught early, medications can reduce the risk of having these complications, restore proper heart function and allow for full recovery within weeks, he added. Movahed's team was able to factor for important variables like age, race, income, chronic lung disease, hypertension and diabetes in the findings. However, there was no patient data on other comorbid diseases, such as a history of stroke or the presence of a Covid-19 infection, Vincent said. Additionally, the new study included in-patient diagnostic data only for those hospitalized with TC, so those who received outpatient care or died later from complications outside the hospital were likely not counted in the analysis, Movahed noted. To establish a firmer explanation for the differences in mortality rates between men and women and further test treatment methods, a more detailed dataset would be needed, Vincent said. 'People should be aware in studies like this, we're presenting findings that are based on diagnostic codes, and we're not looking at patient procedures or lab results,' Vincent said. 'But it's powerful in the sense that it lets us look at large populations and look at trends. And I think that this trend of a higher mortality in men is worth taking a deeper look into.' Sudden, severe chest pain or shortness of breath should always be treated as a medical emergency, warned Bhatt, who is also a professor of cardiovascular medicine at the Icahn School of Medicine at Mount Sinai in New York City. 'It's not a time to tough it out at home or get on the internet to figure it out. … Don't try to track down your primary care provider. Call emergency services,' Bhatt said. 'Time matters. By winning those few hours, you could save yourself irreparable damage to your heart.' Symptoms following physical stressors — a common cause of TC in men — should not be ignored, Movahed said, especially preceding medical events such as asthma attacks, seizures or complications from drug use. And while TC is caused by sudden stress, Bhatt said that managing chronic stress with daily meditation or exercise can lead to better cardiovascular health overall while giving you routines to fall back on in unexpected situations.
